Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crystal Methamphetamine Dependence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Sugar Pill, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 26, 2026, 1:12 PM EDT
Completed No phase listed Observational Results available

Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study

NCT00653263
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Withdrawal
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 26, 2026, 1:12 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

NCT00600145
View directory record Official record
Conditions
Amphetamine Dependence
Interventions
Mirtazapine, Placebo
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT02034201
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
Interventions
quetiapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Methamphetamine Addiction

NCT06899594
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Kevin Murnane
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2Phase 3 Interventional

Prometa Pharmacotherapy for Methamphetamine Dependence

NCT00260481
View directory record Official record
Conditions
Drug Abuse, Drug Dependence
Interventions
Prometa, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Pilot TMS for Methamphetamine Use Disorder

NCT04449055
View directory record Official record
Conditions
Stimulant Dependence, Methamphetamine-dependence, Addiction, Drug
Interventions
Transcranial Magnetic Stimulation--DPFC first, MPFC second, Transcranial Magnetic Stimulation--MPFC first, DPFC second
Device
Lead sponsor
Ryan M. Carnahan
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional Results available

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
bupropion SR
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 3 Interventional

Creatine for Depressed Male and Female Methamphetamine Users

NCT02568878
View directory record Official record
Conditions
Depression, Anxiety, Methamphetamine Dependence
Interventions
Creatine monohydrate
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 26, 2026, 1:12 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Phase 1 Interventional Results available

Safety Assessment of Atomoxetine With MA IV Administration

NCT01019707
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Atomoxetine, then Placebo, Placebo, then Atomoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional

Study of Naltrexone for Methamphetamine Addiction

NCT00984360
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Naltrexone
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

NCT00284206
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

NCT01011829
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Varenicline as a Treatment for Methamphetamine Dependence

NCT01571167
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Placebo, Varenicline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Results available

An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers

NCT00713479
View directory record Official record
Conditions
Methamphetamine Addiction, Crystal Meth Addiction, Amphetamine Addiction
Interventions
Varenicline, then placebo, Placebo, then varenicline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Results available

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT01077024
View directory record Official record
Conditions
Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions
Smoking-cessation treatment
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

NCT00730522
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
CPP-109 vigabatrin, Matching Placebo
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Oceanside, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

Studying Amphetamine Withdrawal in Humans

NCT01215929
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Phase 2 Interventional Results available

Modafinil for Methamphetamine Dependence

NCT00859573
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 26, 2026, 1:12 PM EDT